Financial Performance - INNOVATE Corp's Q2 2025 consolidated revenue was $242 million[16], a decrease of $71.1 million or 22.7% compared to Q2 2024[21] - The company reported a net loss attributable to INNOVATE Corp of $198 million in Q2 2025[17] - Adjusted EBITDA for Q2 2025 was $157 million[20], a decrease of $11 million compared to Q2 2024[21] Segment Performance - Infrastructure (DBMG) - Infrastructure segment revenue decreased to $2331 million in Q2 2025 from $3052 million in Q2 2024[16], a 236% decrease[25] - Infrastructure segment's adjusted EBITDA decreased by $132 million year-over-year[21] to $193 million[17] - DBMG's adjusted backlog remained strong at $13 billion in Q2 2025[12] Segment Performance - Life Sciences (R2 Technologies) - Life Sciences segment revenue increased to $32 million in Q2 2025 from $17 million in Q2 2024[16], an 882% increase[12, 21] - R2 Technologies experienced gross system unit sales growth of 1245% over the prior year quarter worldwide[30] Segment Performance - Spectrum - Spectrum segment revenue decreased to $57 million in Q2 2025 from $62 million in Q2 2024[16] - Spectrum segment reported adjusted EBITDA of $10 million in Q2 2025[12, 17] Debt and Refinancing - On August 4, 2025, INNOVATE closed a series of indebtedness refinancing transactions[12] - Total principal outstanding debt as of June 2025 was $6413 million[35]

Financial Performance & Guidance - Q2 2025 net product sales reached $58.9 million[81] - Q2 2025 contract revenues from collaborations totaled $42.7 million[81] - Rigel increased its 2025 net product sales guidance to a range of $210 million to $220 million, up from the previous guidance of $185 million to $192 million[14, 86] - The company anticipates total revenue for 2025 to be approximately $270 million to $280 million, revised from the initial estimate of $200 million to $210 million[85] - Rigel reported net product sales of $102.5 million YTD[15] Product Performance - Q2 2025 net product sales for TAVALISSE were $40.1 million[26, 83] - Q2 2025 net product sales for GAVRETO were $11.8 million[29, 83] - Q2 2025 net product sales for REZLIDHIA were $7.0 million[29, 83] R&D and Clinical Development - Rigel is evaluating R289, a dual IRAK1/4 inhibitor, in a Phase 1b study for relapsed/refractory lower-risk MDS[13] - The company plans to initiate a Phase 2 study of olutasidenib in recurrent glioma[13] Strategic Collaborations - Collaboration revenues included $40.0 million from Eli Lilly[83] - Grifols contributed $2.0 million in collaboration revenue[35, 83] - Kissei contributed $0.4 million in collaboration revenue[35, 83] - Medison contributed $0.2 million in collaboration revenue[35, 83]

Day One Biopharmaceuticals Targeted therapies for people of all ages August 2025 Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. In some cases, you can identify forward-looking statements by terminology such as "may ...

Forward-looking Statements Certain statements in this presentation constitute forward-looking statements under federal securities laws. These forward-looking statements reflect our views with respect to future events and financial performance as of the date of this presentation or otherwise specified herein. Actual events and results may differ materially from those contemplated by such forward-looking statements due to risks and other factors that are set forth in our Annual Report on Form 10-K and subsequ ...

Financial Performance - Net sales increased by 9% year-over-year, from $282.5 million in Q2 2024 to $309.0 million in Q2 2025[11] - Adjusted EBITDA increased by 12% year-over-year, from $20.5 million in Q2 2024 to $22.9 million in Q2 2025[11] - Adjusted EBITDA margin increased by 16 basis points year-over-year, reaching 7.4% in Q2 2025, the highest margin in 3 years[11] - Net income decreased by 35% year-over-year, from $15.4 million in Q2 2024 to $10.0 million in Q2 2025, primarily due to unfavorable other income/expense comparison and a higher effective tax rate[11] Segment and Geographic Performance - REVOLVE segment net sales increased by 9% year-over-year, from $245.5 million in Q2 2024 to $268.4 million in Q2 2025[16] - FWRD segment net sales increased by 10% year-over-year, from $36.9 million in Q2 2024 to $40.6 million in Q2 2025[16] - U S net sales increased by 7% year-over-year, from $225.1 million in Q2 2024 to $241.6 million in Q2 2025[16] - International net sales increased by 17% year-over-year, from $57.4 million in Q2 2024 to $67.3 million in Q2 2025[16] Operating Metrics - Active customers increased by 7% year-over-year[21] - Total orders placed increased by 6% year-over-year[21] - Average order value decreased by 2% year-over-year, from $306 in Q2 2024 to $300 in Q2 2025[21] Balance Sheet and Cash Flow - Free cash flow for the first half of 2025 was $52.4 million[31] - Cash and cash equivalents increased by $66 million or 27% year-over-year to $310.7 million[36] - The company repurchased 92,583 shares of Class A common stock during Q2 2025 at an average cost of $18.78 per share[36]

Financial Performance - The company's market capitalization is $560 million[5] - Total revenue reached $241 million[5, 9], with Security Solutions contributing $178 million (74%) and Digital Agreements $62 million (26%)[9] - The company's ARR is $178 million[5], with a Net Retention Rate (NRR) of 101%[5] - The company holds $93 million in cash and equivalents[5] - Q2 2025 revenue was $60 million, a decrease of 2%[26] - Q2 2025 subscription revenue grew by 22% to $36 million[26] - Q2 2025 ARR grew by 8% to $178 million[28] - The company paid a quarterly cash dividend of $0.12 per share in Q2 2025[29] Guidance - The company reaffirmed its revenue guidance for FY 2025 at $245 million to $251 million[40] - The company reaffirmed its Adjusted EBITDA guidance for FY 2025 at $72 million to $76 million[40] - The company increased its ARR guidance for FY 2025 to $186 million to $192 million[40] Business Segments - Security Solutions saw a 6% revenue growth, with 9% growth in Software & Services and 27% growth in Subscription revenue[17] - Digital Agreements experienced a 9% revenue growth and 14% Subscription revenue growth[22]

Q2 2025 Investor Presentation Lifetime Data Retention Streaming Architecture High-Performance Indexing 08.05.2025 Forward-Looking Statements and Disclaimer This presentation includes certain "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Other than statements of historical facts, all statements contained in this presentation and accompanying oral commentary, including, but not limited to, statements about Kla ...

Investor Presentation August 2025 Safe Harbor Forward-Looking Statements - This presentation and accompanying oral presentation contain "forward-looking statements" regarding our future performance, including but not limited to estimates regarding revenue, non-GAAP gross margin, and non-GAAP operating margin for the third quarter and fiscal year 2025, statements regarding Arista's addressable market, products and services, innovation and leadership in data-driven AI networking. Forward-looking statements ar ...

Market Opportunity - The near-term market opportunity for Performance TV (PTV) is approaching $120 billion[9, 10, 11] - The U S total advertising market is valued at $399 billion with a CAGR of 6 8% from 2025-2027[13] - The U S performance advertising market is valued at $285 billion with a CAGR of 9 7% from 2025-2027[15] - The U S TV advertising market is valued at $84 billion with a CAGR of 1 1% from 2025-2027[17] Customer Acquisition and Performance - 97% of MNTN's customers had never advertised on TV before[22] - MNTN experienced an 85% increase in active customers for the quarter ended June 30, 2025, compared to the quarter ended June 30, 2024[23] - Tarte's campaigns with MNTN generated 69% more Verified Visits and decreased cost per visit by 34% in 2024 compared to 2023[151] Financial Performance - MNTN's revenue for 2024 was $226 million[97] - MNTN's Adjusted EBITDA for 2024 was $39 million[99] - MNTN's Q2 2025 total revenue was $68 5 million, a 25% total growth[103, 104] - MNTN's Q2 2025 Adjusted EBITDA was $14 5 million, a 92% YoY increase[103]

Financial Performance - Q2 2025 revenue increased by 15% year-over-year[11], and up 12% year-to-date[11] - Q2 revenue increased 11% on a trailing twelve month (TTM) basis[11] - Non-GAAP gross margins were 80.0% in Q2 2025[11] - GAAP EPS was $0.14, compared to $0.13 in Q2 2024[11] - Non-GAAP EPS was $0.21, compared to $0.18 in Q2 2024[11] - Adjusted EBITDA increased from $15.5 million in Q2 2024 to $19.7 million in Q2 2025[16] Revenue Breakdown - Enterprise revenue increased 8% on a TTM basis[11] - Service provider revenue increased 14% on a TTM basis[11] - Service Provider revenue increased from $33.4 million in Q2 2024 to $41.6 million in Q2 2025[20] - In Q2 2025, Americas accounted for 59% of revenue, APJ 26%, and EMEA 15%, with total revenue of $69.4 million[22] Balance Sheet - Cash and cash equivalents were $252.9 million as of June 30, 2025[34] - Marketable securities were $114.5 million as of June 30, 2025[34] - Long-term debt was $218.1 million as of June 30, 2025[34]